Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.

https://ift.tt/2BRZezr